The California-Arizona and Oregon/Hawaii Nodes of the National Drug Abuse Treatment Clinical Trials Network (CTN) integrated their Regional Research and Training Centers (RRTCs) and, in partnership with their community treatment programs (CTPs), combined to propose the Western States Node. In addition to its charter treatment partners, the node expands to include Colorado's network of addiction treatment services - Signal Behavioral Health Network;Signal has prior CTN experience in the Rocky Mountain Node. This competing renewal application has one goal: Promote evidence-based drug abuse prevention and treatment services through our continued participation in the National Drug Abuse Treatment Clinical Trials Network: Design and implement clinical trials of behavioral, pharmacological and combined interventions for drug use disorders through rapid recruitment of diverse study participants in partnership with NIDA and the CTN. Generate peer-reviewed publications in collaboration with treatment providers and other nodes, and Use the CTN as a platform for training, dissemination, and research applications. During the current funding period the California-Arizona and Oregon/Hawaii Nodes, together demonstrated high-quality participation in 12 CTN multi-site clinical trials, involving 13 CTPs and randomizing 900 protocol participants. Node investigators co-led CTN trials of HIV Risk Reduction (CTN0017) and HIV Rapid Testing (CTN0032). Node investigators also sought and received awards for 11 studies that used the CTN as a platform for research. The Western States Node research agenda proposes using the CTN to collaborate with health plans and/or addiction treatment centers to test prevention and treatment interventions directed at reducing the misuse and abuse of prescription opiates. Closing the gap between research and treatment is one of the most critical unresolved issues in drug abuse, and the CTN has a significant role. Based on the Western States Node's experience, access to unique and hard-to-reach populations, and a knowledgeable team of investigators and CTPs, this research node has the potential to accelerate the advancement of clinical trials and translational research in the coming years.

Public Health Relevance

This renewal application to continue conducting translational research in the NIDA Clinical Trials Network has broad public health implications. It focuses on three highly-significant health problems: Drug abuse, HIV/ AIDS, and heath disparities. The project will! conduct clinical trials of treatments for drug use disorders. The project's research agenda will address reducing the abuse of prescription opiates. The project will enable us to identify the effectiveness of these treatments as well as their applicability to a range of hard-to-reach populations. This research can accelerate the advancement of drug abuse treatments in the coming years.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10DA015815-12
Application #
8530188
Study Section
Special Emphasis Panel (ZDA1-KXH-C (04))
Program Officer
Dobbins, Ronald
Project Start
2002-09-30
Project End
2015-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
12
Fiscal Year
2013
Total Cost
$1,120,441
Indirect Cost
$116,132
Name
University of California San Francisco
Department
Psychiatry
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Sanchez, Katherine; Walker, Robrina; Campbell, Aimee N C et al. (2015) Depressive Symptoms and Associated Clinical Characteristics in Outpatients Seeking Community-Based Treatment for Alcohol and Drug Problems. Subst Abus 36:297-303
Campbell, Aimee N C; Turrigiano, Eva; Moore, Michelle et al. (2015) Acceptability of a web-based community reinforcement approach for substance use disorders with treatment-seeking American Indians/Alaska Natives. Community Ment Health J 51:393-403
McCarty, Dennis; Bovett, Rob; Burns, Thomas et al. (2015) Oregon's strategy to confront prescription opioid misuse: a case study. J Subst Abuse Treat 48:91-5
Grazier, Kyle L; Quanbeck, Andrew R; Oruongo, John et al. (2015) What Influences Participation in QI? A Randomized Trial of Addiction Treatment Organizations. J Healthc Qual 37:342-53
Masson, Carmen L; Rainey, Petrie M; Moody, David E et al. (2014) Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals. Am J Addict 23:34-40
Hartung, Daniel M; McCarty, Dennis; Fu, Rongwei et al. (2014) Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies. J Subst Abuse Treat 47:113-21
Flentje, Annesa; Heck, Nicholas C; Sorensen, James L (2014) Characteristics of transgender individuals entering substance abuse treatment. Addict Behav 39:969-75
Peavy, K Michelle; Guydish, Joseph; Manuel, Jennifer K et al. (2014) Treatment adherence and competency ratings among therapists, supervisors, study-related raters and external raters in a clinical trial of a 12-step facilitation for stimulant users. J Subst Abuse Treat 47:222-8
Larios, Sandra E; Masson, Carmen L; Shopshire, Michael S et al. (2014) Education and counseling in the methadone treatment setting improves knowledge of viral hepatitis. J Subst Abuse Treat 46:528-31
McClure, Erin A; Sonne, Susan C; Winhusen, Theresa et al. (2014) Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. Contemp Clin Trials 39:211-23

Showing the most recent 10 out of 93 publications